Researchers from the Wellcome Sanger Institute and the Francis Crick Institute have identified a genetic marker, HLA-DRB1*01:03, that correlates with more severe ulcerative colitis and Crohn’s disease. Published in The Lancet Gastroenterology and Hepatology, the study suggests that genetic testing could help clinicians identify high-risk patients for earlier intervention with advanced therapies.
How does the HLA-DRB1*01:03 marker predict IBD severity?
The genetic variant HLA-DRB1*01:03, located within the HLA-DRB1 gene, is present in approximately one in 20 patients living with inflammatory bowel disease (IBD). According to the study, carrying this specific combination of genetic variants is linked to several severe clinical outcomes.
In patients with Crohn’s disease and ulcerative colitis, the presence of this marker is associated with a higher necessity for colon removal. It also correlates with the development of perianal disease, a condition affecting the skin and tissue around the anus. Additionally, researchers found that patients positive for HLA-DRB1*01:03 showed an increased need for advanced therapies, such as monoclonal antibody treatments and immunosuppressants.
“We found that IBD patients with these genetic variants within the HLA-DRB1 gene had more severe disease, including colon surgeries or advanced treatments, sometimes earlier in their disease progression,” said Dr. Laura Fachal, co-senior author at the Wellcome Sanger Institute.
What makes this the largest genetic study of IBD traits?
The scale of this research sets a new benchmark for understanding the genetic architecture of IBD. Scientists analyzed data from 43,762 patients provided by the NIHR IBD BioResource and the UK IBD Genetics Consortium. This cohort included 21,839 individuals with Crohn’s disease and 21,923 individuals with ulcerative colitis or unclassified IBD.
By studying samples from over 43,000 patients across more than 100 hospitals, the research team was able to draw more definitive links between specific genotypes and disease phenotypes. This large-scale analysis helps address the current challenge of disease unpredictability, where symptoms can range from mild cramping to life-threatening inflammation.
How could genetic testing change IBD treatment?
Current IBD treatments often follow a reactive model, where medication is adjusted based on the severity of symptoms or flare-ups. This study suggests a shift toward a proactive, personalized medicine approach. If genetic testing becomes a standard part of diagnosis, doctors could use the HLA-DRB1*01:03 marker to categorize patients by risk level.
Professor James Lee, co-senior author at the Francis Crick Institute, stated that the study brings researchers closer to building predictors of disease severity. High-risk patients could receive advanced biologics or immunosuppressants earlier in their diagnosis to prevent complications. Conversely, patients identified as lower risk might be managed successfully with conventional, less intensive treatments.
The impact on patient quality of life
For many, the unpredictable nature of IBD causes significant disruption. Imogen, a 26-year-old medical student who was diagnosed with atypical ulcerative colitis at age 13, has undergone multiple surgeries, including a total colectomy. She noted that her symptoms vary significantly from her mother and brother, who also live with IBD.
“If the correct treatment could be identified earlier, it could save a lot of time and suffering for people living with IBD,” Imogen said, noting that the ability to identify targeted treatments is a primary hope for the future of the disease.
Frequently Asked Questions
What is the difference between Crohn’s disease and ulcerative colitis?
Both are forms of inflammatory bowel disease (IBD) that cause gut inflammation. Crohn’s disease can affect any part of the digestive tract, while ulcerative colitis is typically limited to the colon and rectum.
Can genetic testing prevent IBD?
No. Current research focuses on using genetic testing to predict the severity of the disease and how a patient might respond to specific treatments, rather than preventing the onset of the condition itself.
What are “advanced therapies” for IBD?
Advanced therapies often include monoclonal antibody therapies and other biologics designed to target specific parts of the immune system to reduce inflammation.
Do you have questions about how genetic research impacts IBD management? Share your thoughts in the comments below or subscribe to our newsletter for the latest medical research updates.